Following promising findings from an earlier clinical trial, Fulcrum Therapeutics announced yesterday that it will be starting a phase 3 clinical trial of its drug, losmapimod, in people with facioscapulohumeral muscular dystrophy (FSHD), in the second quarter of 2022. The results of the earlier trial showed that people taking the drug had a slowing of condition progression and improved function, compared with people who received placebo.
We've asked the company whether this will include sites in the UK, but they can't release such information at this stage. We'll let you know when we learn more. You can read more about the trial on the Fulcrum website here.